GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-04-19| M&A

GSK Buys Bellus Health For $2 Billion, Lands Chronic Cough Asset

by Joy Lin
Share To

GSK is buying Quebec-based Bellus Health, a late-stage biopharma company, in a deal estimated to be worth $2 billion. GSK will acquire Bellus for $14.75, representing a 103% premium over the Canadian biotech’s closing price of $7.23 the day before. 

Joining GSK’s portfolio is Bellus’ lead candidate, camlipixant, a selective P2X3 antagonist currently in Phase 3 development for the first-line treatment of adult patients with refractory chronic cough (RCC). 

Related article: GSK Bets $593 Million To License Scynexis’ Oral Antifungal 

Camlipixant Inhibits P2X3 to Reduce Cough Frequency

RCC refers to a persistent cough that lasts more than eight weeks and does not respond to treatment for an underlying condition or is idiopathic. Up to 10 million people globally, including 6 million in the US and the EU, suffer from RCC for over a year. 

Clinical data show that by inhibiting P2X3 receptors, camlipixant may reduce cough frequency while being less likely to affect the sense of taste, a side effect which has been linked to medicines that target P2X2/3, such as Merck’s gefapixant. 

Camlipixant is expected to obtain approval and launch in 2026. GSK expects the Bellus purchase to increase its earnings per share (EPS) from 2027, and anticipates significant sales in the next decade and beyond. 

“Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues,” said Luke Miels, Chief Commercial Officer, GSK. “Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential. This proposed acquisition complements our portfolio of specialty medicines and builds on our expertise in respiratory therapies.”

However, once it’s out, camlipixant may have to contend for sales against Merck’s gefapixant. In two Phase 3 trials, gefapixant reported 18.5% and 14.6% reductions in 24-hour cough frequency compared to placebo. Bellus’ candidate, on the other hand, reduced cough frequency by 34% in its Phase 2b. 

GSK will hope to take advantage of camlipixant’s greater selectivity which is less likely to lead to taste disturbance. In Bellus’ Phase 2b trial, taste alteration only occurred in 6.5% of patients, compared to 58% and 59% in Merck’s two Phase 3 studies.  

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP
2025-01-07
GSK Expands Arexvy Approval to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
2024-12-02
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top